Taysha Gene Therapies, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Sean Nolan
- Full Time Employees
- 99
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 3000 Pegasus Park Drive Dallas TX United States of America 75247
- IPO Date
- Sep 24, 2020
- CIK
- 0001806310
- Website
- tayshagtx.com
- Similar Companies
- Business
- Taysha Gene Therapies, Inc. (TSHA) is a clinical-stage biotechnology company focused on discovering, developing and commercializing adeno-associated virus (AAV)-based gene therapies targeting monogenic diseases of the central nervous system (CNS) in rare and larger patient populations; its lead product candidate, TSHA-102, is a self-complementary, intrathecally delivered AAV9 gene transfer therapy incorporating proprietary miRNA-Responsive Auto-Regulatory Element (miRARE) technology to deliver a functional MECP2 gene for Rett syndrome, a rare neurodevelopmental disorder primarily affecting females; the company maintains a pipeline of early-stage programs, including TSHA-120 for giant axonal neuropathy, TSHA-118 for CLN1 disease and TSHA-105 for SLC13A5 deficiency, with certain clinical-stage assets deprioritized for potential external partnerships. Founded in 2019 and headquartered in Dallas, Texas, Taysha collaborates with The University of Texas Southwestern Medical Center on research, licensing and development, while operating primarily in the United States with clinical trials supporting global patient access in major markets including the European Union and United Kingdom. Recent developments include regaining full global rights to TSHA-102 in October 2025 following the expiration of a 2022 strategic investment and collaboration agreement with Astellas Pharma Inc., which had provided $50 million upfront; securing U.S. FDA Breakthrough Therapy Designation for TSHA-102 based on positive REVEAL adult study data showing 100% response in developmental milestone gains as of May 2025; finalizing FDA alignment on the pivotal REVEAL trial protocol and statistical analysis plan with a planned six-month interim analysis to potentially expedite biologics license application submission; and bolstering its balance sheet to $297.3 million in cash and equivalents as of September 30, 2025, supporting accelerated pipeline execution.
Company News
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Bank of America Corp DE Has $7.50 Million Stake in Taysha Gene Therapies, Inc. $TSHA
Taysha Gene Therapies, Inc. (TSHA) Q2 2026 Earnings Call Transcript
Taysha Gene Therapies Q2 Earnings Call Highlights
Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11
Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome
Taysha: 'Buy' On Interim Analysis Of TSHA-102 First Half 2027 And Broad Label Potential
Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting
Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Taysha Gene Therapies, Inc. (TSHA) Discusses Longer-Term Clinical Data and Program Update for TSHA-102 in Rett Syndrome Transcript
Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies: Shortened Timeline Increases The Potential
Taysha Gene Therapies, Inc. (TSHA) Q1 2026 Earnings Call Transcript
Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)